---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014951"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2023-08-15T23:59:59+00:00"
generated_at: "2026-06-11T09:12:46.662488+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Q2 net loss $4.2M ($0.53/sh); positive AML Phase 2 data for prexigebersen

## Summary
- Net loss $4.2M ($0.53/sh) vs $3.0M ($0.42/sh) a year ago; R&D spend up to $3.1M from $1.9M.
- Cash $3.4M at June 30, down from $10.4M at Dec 31, 2022; operating cash burn $6.9M for H1 2023.
- Positive interim Phase 2 data for prexigebersen in AML: well-tolerated, compelling efficacy in newly diagnosed and relapsed/refractory patients.
- Company plans to file for regulatory designations to accelerate pathway for prexigebersen in AML.

## SEC filing metadata
- accession: 0001558370-23-014951
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2023-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/0001558370-23-014951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/bpth-20230815x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014951
- JSON: https://secwatch.observer/filing/0001558370-23-014951.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014951.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: net income $4.2 million, or $0.53 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $4.2 million, or $0.53 per share
  - Result: reported results
  source text: The Company reported a net loss of $4.2 million, or $0.53 per share, for the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837023014951/0001558370-23-014951-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.